Lisa Pope Westerman has created LUCID, a network of architects that's flipping the script on how architecture projects go. Courtesy of LUCID

What if retaining one architecture company gave you access to dozens more? That's the idea behind LUCID, an architecture and design collective that Lisa Pope Westerman, formerly of San Francisco-based Gensler and New York City-based rockwell group, launched in Houston this year.

LUCID is a collective of architects and boutique architecture firms that specialize in at least one of the following property types: hospitality, retail, mixed-use developments, high-rise residential, and wellness developments. When clients retain LUCID as their designer or architect, they're given access to the firms and individual architects who are best suited for the job. Currently, LUCID is composed of roughly 40 total architects coming from several architecture and design firms, including Chicago-based PinPoint Collective, Houston-based gin design group, and New York-based Glen & Co. architecture.

"People have referred to us as 'the WeWork of architecture,' or 'the Uber of design,'" Pope Westerman says. "We think that in 10 years, this is how the world will just be working."

Pope Westerman spoke with InnovationMap about launching LUCID, Houston's unique design community and how the architecture industry continues to innovate.

InnovationMap: When did you start planning LUCID?

Lisa Pope Westerman: I really started thinking about it in beginning of 2018, and working on it middle of 2018, and making sure the initial groups we started with are a good fit. It's been nothing but wonderful. Everyone's smarter than me, and brings such a unique perspective to the group for various reasons. Not everyone is an architect or an interior designer ­– the intent is to be really nimble and flexible. We're bringing a lot of unique specialists. We have branding, graphic design, and a strategy group that is just amazing.

We're looking to, as a group, not just be innovative, but have innovation in all the different types of things [we offer], including our process. We believe that the world of design is going to be much more than visual, and that we really need to be thinking about all the senses, like touch and smell and [hearing]. Just typically, everything's visual, and [the other senses] have been secondary.

IM: How did LUCID find the architects and architecture firms that compose the collective?

LPW: The original of roughly 40 people are people I've worked with over the past 20 years. That's how we got things started. I've basically been involved in every size company imaginable: from a one-man show, to the largest design firm in the world, Gensler. The intent of the model is to create something where there's a parent brand that feels like a very large company, and we're essentially an umbrella, and within us are all the other wonderful boutique specialty brands.

IM: What kinds of architecture firms does LUCID work with?

LPW: Most of the firms affiliated with us are around a dozen people. We find that's the right size of people that are highly specialized, super talented, and able to maintain the [high] quality level.

IM: Tell me a bit about LUCID's business model.

LPW: So, we facilitate everything, and that's how [LUCID] is compensated. So, we essentially facilitate in bringing the companies to the client, which is the business development aspect of things. We collaborate on the client management side, so we're still very involved with the clients and the projects. We carry everybody. We help manage all of it, and all of the companies' [projects]. It's a true collaboration.

People truly believe that by being associated with LUCID, they're going to be able to elevate what they've been doing even more. It's important that the companies that want to be affiliated with LUCID are really interested in that.

IM: Can the architecture firms that are a part of LUCID still do work outside of the LUCID collective?

LPW: All the firms connected to LUCID still do their own business. They haven't folded into LUCID and then given up their brand. The intent is that we're celebrating the brands. We like the diversity.

IM: LUCID is currently working on its first project. What information can you share?

LPW: It's in the hospitality industry, and it is a restaurant, bar, event space, and it's for a private club outside of Houston. We started at the beginning of [2019], and we'll be done at the end of the year.

IM: Did LUCID launch with a fund raise? Are you planning a fund raise?

LPW: The front end is really just a shared passion among the companies and individuals that are connected. Longer term, we are interested in even partnering with investors in creating new and different kinds of projects. There are some other firms out there, but not many, that are starting to do that sort of thing … where [the design firm] collaborates with investors and projects, rather than just being hired on as the designer for a project.

IM: How is the Houston design scene different from design scenes around the world?

LPW: Well, I think it's an exciting time for Houston. Especially in our world of lifestyle design, it's the overarching [theme]. We do everything for lifestyle. In Houston, we're really starting to be at the height of this renaissance of bringing just a higher level of appreciation for design. From a lifestyle standpoint, things have been percolating for a while now.

IM: What's a foundational project you've worked on that taught you an essential lesson about design?

LPW: In terms of my Houston project base, certainly the ExxonMobil project was really impactful, because of the scale of the project and all the different participants in it. We collaborated with several other design firms, both in Houston and out of Houston, and not only design firms, but also globally acclaimed artisans. Just at a worldwide level, the caliber of the clients was amazing. It was an incredible experience because of the scale and the success of it. … It was building a city.

------

Portions of this interview have been edited.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Houston researchers develop dissolvable implant for targeted cancer drug delivery

cancer research

Researchers at Houston Methodist have developed a biodegradable implant that can be used to safely and consistently deliver drug treatments to tumors and then dissolve without the need for further surgery.

The implant is only the size of a grain of rice, but its potential is staggering. The biodegradable nanofibrous drug-eluting seed (b-NDES) works as a reservoir parked inside a soft tumor, where it can slowly release immune-stimulating drugs over time. This overcomes a consistent problem with drugs such as immune checkpoint inhibitors. Normal systemic administration sees comparatively little of the drug making its way to the tumor, with most of it circulating throughout the body. The b-NDES is like deploying a small guerrilla fighting force embedded in enemy territory, doing maximum damage to the entrenched tumor.

"To improve cancer treatment, we're trying to start a fire inside the tumor itself," Corrine Chua, associate professor in the Center for BioNanoengineering at Houston Methodist Research Institute, said in a news release. "By activating immune cells directly within the tumor microenvironment, those cells can then travel throughout the body and seek out cancer wherever it exists. The b-NDES platform was developed to help keep therapeutic drugs concentrated inside tumors while minimizing exposure to healthy tissues.”

Chua co-led the study with Alessandro Grattoni, chair and director of the Center for BioNanoengineering at Houston Methodist Research Institute.

The study included support from the Nancy Owens Breast Cancer Foundation and the National Institutes of Health/National Cancer Institute.

Chau and Grattoni used preclinical models of triple-negative breast cancer, an aggressive form of cancer that is estrogen receptor-negative, progesterone receptor-negative and HER2-negative. Because of the receptor negativity, some popular treatments like tamoxifen and trastuzumab are ineffective. Chemotherapy has been shown to be the best course of action.

The b-NDES implant is deployed alongside radiation drugs. It keeps the drugs focused on the tumor, reducing the amount of harmful side effects typically seen when drugs are circulated more widely in the body. In 60 percent of the models, tumors were eliminated and did not cause side effects beyond the tumor site. Once the drugs have been deployed, the implant breaks down naturally.

While promising, more research will have to be done to expand use to other tumor types.

"Although the study focused on triple-negative breast cancer models, the approach could have broader applications for solid tumors," Grattoni added in the release. "It could potentially be used in cancers where there is a tumor lesion accessible for placement, including pancreatic or lung cancers."

New Houston platform Same Day Reels launches for on-demand content creation

In The Moment

If an event doesn't happen on Instagram, did it even really happen? In today's social media-driven age of branding and audience engagement, the answer increasingly is no.

Houston entrepreneur Karen De Amat is looking to fill the online content creation needs of companies with her new venture, Same Day Reels, which launched in early August. It will serve as a platform to connect companies and brands with talent that can help turn an event into a viral moment as it is happening.

"Events move quickly, and social media moves even faster,” said De Amat. “Same Day Reels was built to help brands capture the moment while it still matters. We are creating a more efficient way for businesses and creators to work together. Brands need content faster, and creators need more opportunities to turn their talent into real work. Same Day Reels brings those needs together.”

The company is focused on adding livestreams and concurrent short video content to "activations, launches, fundraisers, grand openings, conferences, hospitality experiences, and private celebrations." Such content can significantly increase the visibility of a product or brand according to digital marketing brands like Wyzowl, whose data found 63 percent of people in 2026 prefer to learn about new products via short video.

Packages offered by Same Day Reels will include filming, editing, and publishing content within hours of the targeted event.

De Amat says that her content creation platform will be a way to preserve the excitement of events and launches by enshrining them with immediate social media-driven memories.

“Event content is no longer just something you post after the fact,” De Amat said. “It is part of how people experience, remember and share the moment.”

Previously, De Amat is also the founder and CEO of Social Behavior, an influencer marketing company she launched from her home in 2014. It quickly garnered an array of clients and thrust De Amat into the spotlight, including numerous appearances on Fox 26's The Isiah Factor. Influencer Marketing Hub named her one of the top CEOs of influencer marketing companies in Houston in 2025.

---

This article originally appeared on CultureMap.com.

Bristol Myers Squibb to build $2.3B Houston pharma manufacturing campus

coming soon

New Jersey-based pharmaceutical giant Bristol Myers Squibb Co. has officially named Houston as the home of its new state-of-the-art manufacturing site.

The 60,000-square-foot facility represents a $2.3 billion investment, according to a news release. It is expected to create 500 skilled jobs and will be located in Houston's Generation Park.

BMS first announced that it was considering Houston among 16 other cities for the facility in May. The new hub will manufacture small molecule, biologic and antibody-drug conjugates and is part of a $40 billion commitment to invest in the United States over five years. Construction is slated to begin next year, with the facility coming online in 2030.

"We're building the domestic manufacturing capabilities needed to deliver the next generation of medicines and support future scientific breakthroughs. Houston and the state of Texas offer the talent, infrastructure, and partnership needed to help bring that vision to life," Christopher Boerner, CEO and board chair of BMS, said in the release.

The new facility will feature a modular, multi-modal design, which will allow the company to reconfigure and add to its manufacturing capabilities over time. BMS says it expects the facility to "(grow) in scale and capability well beyond its opening configuration."

"Our decision to build this state-of-the-art manufacturing campus in Houston, Texas, reflects our confidence in the region’s ability to support a world-class, digitally advanced supply operation,” Karin Shanahan, EVP and chief supply chain and operations officer of BMS, added in the release. “This facility is designed to deliver the speed, quality, and reliability that patients depend on, combining flexible, modular manufacturing with advanced digital capabilities to ensure consistent supply across multiple modalities. It strengthens our ability to operate with resilience and positions us to reliably deliver medicines to patients today while adapting future demands.”

Texas Gov. Greg Abbott shared that the state has granted BMS a $4.89 million Texas Enterprise Fund (TEF) grant for the project. TEF grants, administered by the Texas Economic Development & Tourism Office, support business relocation or expansion projects that create "new, good-paying jobs in the community and attract significant new capital investment to the state." The development is also a qualified project under the Texas Jobs, Energy, Technology, and Innovation (JETI) program.

“Texas is a global hub for life sciences, where today’s innovations shape the future of healthcare,” Abbott said in a news release. “This $2.3 billion investment by Bristol Myers Squibb in the dynamic biotech ecosystem in Houston is a testament to the depth of our skilled workforce and the pipeline of talent coming through our nation-leading technical colleges and research universities. With lower operating costs and easy access to markets across the U.S. and the world, Texas drives affordability for consumers.”

"Bristol Myers Squibb’s announcement is a tremendous win for Texas and the Houston region, further reinforcing our position as a premier destination for life sciences and advanced manufacturing,” added Greater Houston Partnership President and CEO Steve Kean.

Last fall, Eli Lilly and Co. selected Generation Park, a 4,300-acre, master-planned commercial district near Lake Houston, for its $6.5 billion manufacturing plant. More than 300 locations in the U.S. competed for the factory. Read more here.